Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir

European Journal of Clinical Pharmacology

Volumn 66, Issue 10, 2010, Pages 977-985

  Nieminen, Tuija H ^a   Hagelberg, Nora M ^a   Saari, Teijo I ^a   Neuvonen, Mikko ^b   Neuvonen, Pertti J ^b   Laine, Kari ^c   Olkkola, Klaus T ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Interaction; Lopinavir ritonavir; Oxycodone; Pharmacodynamics; Pharmacokinetics; Ritonavir

Indexed keywords

LOPINAVIR PLUS RITONAVIR; OPIATE AGONIST; OXYCODONE; OXYMORPHONE; PLACEBO; RITONAVIR; TROPISETRON;

ABDOMINAL DISCOMFORT; ADULT; ANALGESIA; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COLD PRESSOR TEST; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; EVENING DOSAGE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NAUSEA AND VOMITING; NORMAL HUMAN; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FINLAND; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LINEAR MODELS; MALE; OXYCODONE; PAIN; PYRIMIDINONES; REFERENCE VALUES; RITONAVIR; TIME FACTORS; YOUNG ADULT;

EID: 77957657935     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0879-1     Document Type: Article

References (49)

1. KA Lee C Gay CJ Portillo T Coggins H Davis CR Pullinger BE Aouizerat 2009 Symptom experience in HIV-infected adults: a function of demographic and clinical characteristics J Pain Symptom Manage 38 882 893 10.1016/j.jpainsymman. 2009.05.013 19811886
2. LM Frich FM Borgbjerg 2000 Pain and pain treatment in AIDS patients: a longitudinal study J Pain Symptom Manage 19 339 347 1:STN:280: DC%2BD3czjtVWrtw%3D%3D 10.1016/S0885-3924(00)00140-8 10869874
3. G Gray P Berger 2007 Pain in women with HIV/AIDS Pain 132 Suppl 1 S13 S21 10.1016/j.pain.2007.10.009 17959310
4. S Verma L Estanislao D Simpson 2005 HIV-associated neuropathic pain: epidemiology, pathophysiology and management CNS Drugs 19 325 334 10.2165/00023210-200519040-00005 15813646
5. UA Walker A Tyndall T Daikeler 2008 Rheumatic conditions in human immunodeficiency virus infection Rheumatology (Oxford) 47 952 959 1:STN:280:DC%2BD1czovFeksA%3D%3D 10.1093/rheumatology/ken132
6. R Freynhagen MI Bennett 2009 Diagnosis and management of neuropathic pain BMJ 339 b3002 1:STN:280:DC%2BD1MrltFyisw%3D%3D 10.1136/bmj.b3002 19675082
7. E Kalso 2005 Oxycodone J Pain Symptom Manage 29 S47 S56 1:CAS:528:DC%2BD2MXlslCltL4%3D 10.1016/j.jpainsymman.2005.01.010 15907646
8. R Pöyhiä T Seppälä KT Olkkola E Kalso 1992 The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects Br J Clin Pharmacol 33 617 621 1389934
9. B Lalovic B Phillips LL Risler W Howald DD Shen 2004 Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes Drug Metab Dispos 32 447 454 1:CAS:528: DC%2BD2cXis1ehuro%3D 10.1124/dmd.32.4.447 15039299
10. E Boström US Simonsson M Hammarlund-Udenaes 2005 Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833 J Pharm Sci 94 1060 1066 10.1002/jps.20327 15799017
11. HE Hassan AL Myers IJ Lee A Coop ND Eddington 2007 Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats J Pharm Sci 96 2494 2506 1:CAS:528:DC%2BD2sXhtVWntLfE 10.1002/jps.20893 17593551
12. E Boström US Simonsson M Hammarlund-Udenaes 2006 In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics Drug Metab Dispos 34 1624 1631 10.1124/dmd.106.009746 16763013
13. HH Villesen DJ Foster RN Upton AA Somogyi A Martinez C Grant 2006 Cerebral kinetics of oxycodone in conscious sheep J Pharm Sci 95 1666 1676 1:CAS:528:DC%2BD28XnvF2it7s%3D 10.1002/jps.20632 16729270
14. T Okura A Hattori Y Takano T Sato M Hammarlund-Udenaes T Terasaki Y Deguchi 2008 Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone Drug Metab Dispos 36 2005 2013 1:CAS:528:DC%2BD1cXhtF2jtLbI 10.1124/dmd.108.022087 18606742
15. C Debouck 1992 The HIV-1 protease as a therapeutic target for AIDS AIDS Res Hum Retroviruses 8 153 164 1:CAS:528:DyaK2cXlvFClsbk%3D 10.1089/aid.1992.8. 153 1540403
16. KT Olkkola VJ Palkama PJ Neuvonen 1999 Ritonavir's role in reducing fentanyl clearance and prolonging its half-life Anesthesiology 91 681 685 1:CAS:528:DyaK1MXmsVWrtL0%3D 10.1097/00000542-199909000-00020 10485779
17. RE Aarnoutse J Kleinnijenhuis PP Koopmans DJ Touw J Wieling YA Hekster DM Burger 2005 Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers Clin Pharmacol Ther 78 664 674 1:CAS:528:DC%2BD2MXhtlShsLbM 10.1016/j.clpt.2005.09.001 16338282
18. ED Kharasch PS Bedynek A Walker D Whittington C Hoffer 2008 Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities Clin Pharmacol Ther 84 506 512 1:CAS:528:DC%2BD1cXhtFeitbnJ 10.1038/clpt.2008.102 19238656
19. P Liu G Foster K Gandelman RR LaBadie MJ Allison MJ Gutierrez A Sharma 2007 Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects Antimicrob Agents Chemother 51 3617 3626 1:CAS:528:DC%2BD2sXhtFGhtbjK 10.1128/AAC.00526-07 17646413
20. ED Kharasch D Mitchell R Coles R Blanco 2008 Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir Antimicrob Agents Chemother 52 1663 1669 1:CAS:528:DC%2BD1cXls1ajtbk%3D 10.1128/AAC.01600-07 18285471
21. A Hsu GR Granneman RJ Bertz 1998 Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents Clin Pharmacokinet 35 275 291 1:CAS:528:DyaK1cXnsVWrsrY%3D 10.2165/00003088-199835040-00002 9812178
22. RS Cvetkovic KL Goa 2003 Lopinavir/ritonavir: a review of its use in the management of HIV infection Drugs 63 769 802 1:CAS:528:DC%2BD3sXjsF2gtb8%3D 10.2165/00003495-200363080-00004 12662125
23. RF Yeh VE Gaver KB Patterson NL Rezk F Baxter-Meheux MJ Blake JJ Eron Jr CE Klein JC Rublein AD Kashuba 2006 Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers J Acquir Immune Defic Syndr 42 52 60 1:CAS:528:DC%2BD28XlsFGqtrY%3D 16639344
24. C Wyen U Fuhr D Frank RE Aarnoutse T Klaassen A Lazar A Seeringer O Doroshyenko JC Kirchheiner F Abdulrazik N Schmeisser C Lehmann W Hein E Schomig DM Burger G Fatkenheuer A Jetter 2008 Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients Clin Pharmacol Ther 84 75 82 1:CAS:528:DC%2BD1cXnt1Kqs7c%3D 10.1038/sj.clpt.6100452 18183034
25. NM Hagelberg TH Nieminen TI Saari M Neuvonen PJ Neuvonen K Laine KT Olkkola 2009 Voriconazole drastically increases exposure to oral oxycodone Eur J Clin Pharmacol 65 263 271 1:CAS:528:DC%2BD1MXitVyiu7Y%3D 10.1007/s00228-008- 0568-5 18836708
26. TI Saari J Grönlund NM Hagelberg M Neuvonen K Laine PJ Neuvonen KT Olkkola 2010 Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone Eur J Clin Pharmacol 66 387 397 1:CAS:528:DC%2BC3cXjtlansb0%3D 10.1007/s00228-009-0775-8 20076952
27. J Grönlund T Saari N Hagelberg IK Martikainen PJ Neuvonen KT Olkkola K Laine 2010 Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone J Clin Pharmacol 50 101 108 10.1177/0091270009336444 19755414
28. E Michna EL Ross WL Hynes SS Nedeljkovic S Soumekh D Janfaza D Palombi RN Jamison 2004 Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history J Pain Symptom Manage 28 250 258 10.1016/j.jpainsymman.2004.04.007 15336337
29. J Sistonen S Fuselli A Levo A Sajantila 2005 CYP2D6 genotyping by a multiplex primer extension reaction Clin Chem 51 1291 1295 1:CAS:528: DC%2BD2MXlsleqsbs%3D 10.1373/clinchem.2004.046466 15905314
30. M Neuvonen PJ Neuvonen 2008 Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography- electrospray-tandem mass spectrometry Ther Drug Monit 30 333 340 1:CAS:528:DC%2BD1cXmsFyntrY%3D 10.1097/FTD.0b013e31816e2d4b 18520605
31. NL Rezk NR White SH Jennings AD Kashuba 2009 A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma Talanta 79 1372 1378 1:CAS:528:DC%2BD1MXptV2lsLo%3D 10.1016/j.talanta.2009.06.005 19635373
32. TH Nieminen NM Hagelberg TI Saari A Pertovaara M Neuvonen K Laine PJ Neuvonen KT Olkkola 2009 Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone Anesthesiology 110 1371 1378 1:CAS:528: DC%2BD1MXmtFKntb8%3D 10.1097/ALN.0b013e31819faa54 19417618
33. AJ Bond MH Lader 1974 The use of analoque scales in rating subjective feelings Br J Med Psychol 47 211 218
34. JG Hannington-Kiff 1970 Measurement of recovery from outpatient general anaesthesia with a simple ocular test Br Med J 3 132 135 1:STN:280: DyaE3c3ktFSmsQ%3D%3D 10.1136/bmj.3.5715.132 5431082
35. BM Stone 1984 Pencil and paper tests-sensitivity to psychotropic drugs Br J Clin Pharmacol 18 15S 20S 6151847
36. DG Cogan 1941 Simplifiied entoptic pupillometer Am J Ophthalmol 24 1431 1433
37. SF Jones HJ McQuay RA Moore CW Hand 1988 Morphine and ibuprofen compared using the cold pressor test Pain 34 117 122 1:CAS:528:DyaL1cXlt1Wqs7c%3D 10.1016/0304-3959(88)90156-X 3174150
38. CS Ernest 2nd SD Hall DR Jones 2005 Mechanism-based inactivation of CYP3A by HIV protease inhibitors J Pharmacol Exp Ther 312 583 591 1:CAS:528:DC%2BD2MXhsVCnsb0%3D 10.1124/jpet.104.075416 15523003
39. MT Granfors JS Wang LI Kajosaari J Laitila PJ Neuvonen JT Backman 2006 Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro Basic Clin Pharmacol Toxicol 98 79 85 1:CAS:528:DC%2BD28XhsFegsbk%3D 10.1111/j.1742-7843.2006.pto- 249.x 16433896
40. DJ Greenblatt LL von Moltke JS Harmatz AL Durol JP Daily JA Graf P Mertzanis JL Hoffman RI Shader 2000 Alprazolam-ritonavir interaction: implications for product labeling Clin Pharmacol Ther 67 335 341 1:CAS:528:DC%2BD3cXjsV2qurw%3D 10.1067/mcp.2000.105757 10801241
41. D Ouellet A Hsu GR Granneman G Carlson J Cavanaugh H Guenther JM Leonard 1998 Pharmacokinetic interaction between ritonavir and clarithromycin Clin Pharmacol Ther 64 355 362 1:STN:280:DyaK1M%2FhsVGhtw%3D%3D 10.1016/S0009- 9236(98)90065-0 9797791
42. A Hsu GR Granneman G Witt C Locke J Denissen A Molla J Valdes J Smith K Erdman N Lyons P Niu JP Decourt JB Fourtillan J Girault JM Leonard 1997 Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects Antimicrob Agents Chemother 41 898 905 1:CAS:528:DyaK2sXjtVCnt7Y%3D 9145841
43. ED Kharasch C Hoffer D Whittington A Walker PS Bedynek 2009 Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir Anesthesiology 110 660 672 1:CAS:528:DC%2BD1MXit1Sgsbc%3D 10.1097/ALN.0b013e3181986a9a 19225389
44. JL Weemhoff LL von Moltke C Richert LM Hesse JS Harmatz DJ Greenblatt 2003 Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir J Pharm Pharmacol 55 381 386 1:CAS:528:DC%2BD3sXjs1eiu7o%3D 10.1211/002235702739 12724045
45. GN Kumar AD Rodrigues AM Buko JF Denissen 1996 Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes J Pharmacol Exp Ther 277 423 431 1:CAS:528:DyaK28XitlCmtbc%3D 8613951
46. ST Zwisler TP Enggaard S Mikkelsen K Brosen SH Sindrup 2010 Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia Acta Anaesthesiol Scand 54 232 240 1:CAS:528:DC%2BC3cXhvFWqsbc%3D 10.1111/j.1399-6576.2009.02104.x 19719813
47. RD Bruce FL Altice DE Moody SN Lin WB Fang JP Sabo JM Wruck PJ Piliero C Conner L Andrews GH Friedland 2009 Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone Drug Alcohol Depend 105 234 239 1:CAS:528:DC%2BD1MXht1yisrrM 10.1016/j.drugalcdep.2009.07.007 19726139
48. MJ van der Lee L Dawood HJ ter Hofstede MJ de Graaff-Teulen EW van Ewijk-Beneken Kolmer N Caliskan-Yassen PP Koopmans DM Burger 2006 Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects Clin Pharmacol Ther 80 159 168 10.1016/j.clpt.2006.04.014 16890577
49. B Lalovic E Kharasch C Hoffer L Risler LY Liu-Chen DD Shen 2006 Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites Clin Pharmacol Ther 79 461 479 1:CAS:528:DC%2BD28XktVegsb4%3D 10.1016/j.clpt.2006.01.009 16678548